ADALIMUMAB
adalimumab 80 mg/0.8 mL injection, 0.8 mL syringe
ADALIMUMAB (12395J)
12395J
Manner of administration:Injection
Restriction
Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a
break in biological medicine of less than 5 years), or Initial 3 (recommencement of
treatment after a break in biological medicine of more than 5 years) - balance of
supply
